Pharmalot

Pharmalot By Ed Silverman

Pharmalittle: FDA declines to approve two more drugs tested in China; Pfizer Covid pill fails to prevent infection in household members

Pharmalot By Ed Silverman

U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare

Pharma By Ed Silverman

The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant

Pharmalot By Ed Silverman

California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?

Pharmalot By Ed Silverman

Pharmalittle: Amgen faces $7B IRS back-tax bill and fine; McKinsey exec apologizes for opioid work during hearing

Pharma By Ed Silverman

Pharmalittle: J&J sues wholesalers and a pharmacy over fake HIV meds; Rite Aid to pay $123 million to Humana for inflating drug prices

Pharmalot By Ed Silverman

Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims

Pharma By Ed Silverman

Pharmalittle: White House announces Covid-pill push; ‘right-to-try’ think tank is back with a new law

Pharmalot By Ed Silverman

Thanks to Covid-19, pharma’s reputation improved among patient groups. But can it last?

Pharmalot By Ed Silverman

Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review

Pharmalot By Ed Silverman

One in four pharma status reports on follow-up trials are late or aren’t filed

Pharmalot By Ed Silverman

Pharma R&D payments to European researchers are like ‘dark money’

Pharmalot By Ed Silverman

Pharmalittle: Are new ADHD treatments really any better? India moves to reduce dependence on China for pharma ingredients

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: U.S. health agency workers fail to report political interference; Canada walks back some drug-pricing reforms

Pharmalot By Ed Silverman

Pharmalittle: U.S. spending on medicines rose 12% last year; Louisiana sues a PBM for allegedly overcharging

Pharmalot By Ed Silverman

U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies

Pharmalot By Ed Silverman

Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions

Pharmalot By Ed Silverman

Louisiana accuses UnitedHealth and its OptumRx PBM of inflating drug costs for its Medicaid program

Pharmalot By Ed Silverman

Pfizer faces criticism for arguing that intellectual property for its Covid-19 pill is a human right

Pharmalot By Ed Silverman

Pharmalittle: Glaxo workers in the U.K. vote to strike; Alabama reaches $276 million deal over opioid crisis

Pharmalot By Ed Silverman

Pharmalittle: Global demand for Pfizer Covid-19 pill falls; biotech hub in Massachusetts set for a correction

Pharmalot By Ed Silverman

Animal rights group urges USDA to probe research facilities for failing to inspect monkey shipments

Pharmalot By Ed Silverman

Pharmalittle: U.K watchdog agency is urged to bolster conflicts policy; FDA device program helps makers more than patients

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: WTO head says Covid vaccine IP talks are nearing agreement; RSV is the next big target for vaccine makers

Pharmalot By Ed Silverman

Bristol Myers agrees to settle lawsuit alleging anti-competitive deals involving HIV drugs